Corporate Banner
Satellite Banner
Technology Networks Header
Monday, October 20, 2014
Technology Networks
 
Register | Sign in
Home Page > Latest Webcasts
  Webcasts
Scientific News
Misfolded Proteins Clump Together in a Surprising Place
Stowers researchers create new framework for protein aggregation under acute stress.
Nanoparticle Research Could Enhance Drug Delivery Through Skin
A milestone study from the University of Southampton could have major implications for the delivery of drugs.
Chemists Recruit Anthrax to Deliver Cancer Drugs
With some tinkering, a deadly protein becomes an efficient carrier for antibody drugs.
Protein ‘Map’ Could Lead to Potent New Cancer Drugs
Findings will help scientists to design drugs that could target NMT enzyme.
Animal Testing can Mislead Drug Discovery and Development
Several blockbuster drugs would not be on the market, if scientists had relied solely on drug-uptake in animal trials, according to new research.
Synthesis and Bioactivity of Analogues of Tropodithietic Acid
The study suggests that the sulfur atoms in the marine antibiotic TDA are not essential for bioactivity, but different modes of action for TDA and its sulfur-free analogue cannot be excluded.
Cancer-Fighting Drugs Might Also Stop Malaria Early
A number of compounds have been identified which could be used to fight malaria.
Collaboration Leads to Possible Shortcut to New Drugs
The reaction, reported in Science, demonstrates how a carboxylic acid can be transformed into a very reactive site through use of a novel photoredox catalyst.
Catalysts That Mimic Enzymes Could Revolutionize Pharmaceutical Manufacturing
Structures made of polymer chains allow the catalysts to work in water.
Discovery of How Taxol Works Could Lead to Better Anticancer Drugs
The drug’s interference with the normal function of microtubules could help in designing better anticancer drugs.
Scroll Up
Scroll Down
Return
‘Better Compounds Faster’ – The Development and Exploitation of a Desktop Predictive Chemistry Toolkit
John Cumming, Global Programme Manager for Predictive Chemistry, AstraZeneca R&D, speaking at Medchem Europe 2011.
Date Posted: Thursday, December 01, 2011
Print Page

For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here



AstraZeneca Buys Rights to Almirall Respiratory Franchise
AstraZeneca agrees an initial consideration of $875 million on completion, which may rise to $1.22 billion in development, launch, and sales-related milestones.
Monday, August 04, 2014
AstraZeneca Reveals Designs for Cambridge Headquarters
Company revealed the proposed designs for its new Global R&D Centre and Corporate Headquarters in Cambridge in the UK.
Friday, July 18, 2014
AstraZeneca Board Rejects Pfizer Proposal
The financial and other terms of the proposal have been described as inadequate, substantially undervaluing AstraZeneca.
Friday, May 02, 2014
AstraZeneca to Acquire Bristol-Myers Squibb Share of Global Diabetes Alliance Assets
Global agreement strengthens AstraZeneca’s commitment to diabetes.
Monday, December 23, 2013
AstraZeneca Announces Changes to Senior Executive Team
Company’s President and Executive Vice President will leave the company at the end of January.
Monday, January 28, 2013
AstraZeneca Appoints Pascal Soriot CEO
Pascal Soriot will take on his new responsibilities and join the AstraZeneca PLC Board as an Executive Director on 1 October 2012.
Tuesday, August 28, 2012
AstraZeneca to Provide UK Academics with Access to Compound Library
Their groundbreaking new collaboration with the Medical Research Council (MRC) will see the company providing the UK academic sector with access to 22 drugs.
Friday, December 09, 2011
Forest Laboratories and AstraZeneca to Co-Develop and Commercialize a Late Stage Next Generation Anti-Infective
The definitive collaboration agreement will co-develop and commercialize ceftaroline in all markets outside the U.S., Canada and Japan.
Thursday, August 13, 2009
IRESSA Receives Marketing Authorization for the Treatment of Non-Small Cell Lung Cancer in Europe
European Commission grants marketing authorization for the oral anti-cancer drug.
Tuesday, July 07, 2009
BioDuro and AstraZeneca Expand Collaboration to Optimize Discovery Research for Respiratory and Inflammation Indications
BioDuro and AstraZeneca announced that they have expanded their research collaboration to optimize discovery research for Respiratory and Inflammation indications.
Friday, March 27, 2009
AstraZeneca Licenses Antidepressant Compounds Discovered by Mayo Clinic and Virginia Tech Collaboration
The agreement provides AstraZeneca with a global license for all uses of the compounds, as well as exclusive manufacturing and commercial rights.
Tuesday, February 10, 2009
AstraZeneca and MAP Collaborate for Development and Commercialization of Unit Dose Budesonide
Unit Dose Budesonide is being developed as a potential treatment for pediatric asthma and is currently in Phase III clinical development.
Monday, December 22, 2008
AstraZeneca Announces Partnership with Singapore Institutions to Develop Anti-Cancer Compounds
The collaboration aims to further build AstraZeneca's drug development capabilities in Asia and speed up access to new medicines of potential benefit to patients.
Tuesday, August 19, 2008
Palatin Technologies Announces Amendment Expanding AstraZeneca Obesity Collaboration
AstraZeneca and Palatin amend their collaboration agreement to discover, develop and commercialize compounds that target melanocortin receptors.
Wednesday, July 02, 2008
AstraZeneca Submits sNDAs for Seroquel XR™ for the Treatment of Bipolar Mania and Bipolar Depression
AstraZeneca has submitted two separate supplemental New Drug Applications to the US FDA for once-daily Seroquel XR™ Extended-Release Tablets.
Thursday, January 03, 2008
 
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv